Distributions and prognostic effects of ABO/Rh blood groups in patients with HER2/neu positive gastric and gastroesophageal junction cancer

被引:0
|
作者
Dogan, Izzet [1 ]
Gurbuz, Mustafa [2 ]
Aydin, Esra [1 ]
Karabulut, Senem [1 ]
Tastekin, Didem [1 ]
Utkan, Gungor [2 ]
机构
[1] Istanbul Univ Inst Oncol, Med Oncol, Istanbul, Turkiye
[2] Ankara Univ, Med Oncol, Fac Med, Ankara, Turkiye
关键词
ABH blood group; gastric cancer; HER2/neu receptor; risk factors; RISK;
D O I
10.4103/jcrt.jcrt_1520_22
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The aim of study was to look at ABO/Rh blood types frequency and prognostic significance in patients with HER2/neu positive gastric cancer. Methods: The study was designed retrospectively. Clinicopathological characteristics, treatment approaches, and the ABO/Rh blood groups features were noted. The ABO/Rh blood types for patients and healthy donors were compared by the Chi-square method. Results: The average age was 61 years. The average survival time was 17.9 months (13.2-22.5). ABO blood types frequencies were not similar between patients (25.9% O, 6.3% AB, 57.1% A, and 10.7% B) and control group (34.9% O, 7.9% AB, 41.9% A, and 15.3% B) (P = 0.01). Patients and controls had the same Rh factor distribution (P = 0.07). Conclusions: We showed that A blood group frequency was increased in patients with HER2/neu receptor-positive gastric cancer than in a healthy population. Also, we detected that the frequency of O blood type was decreased. ABO/Rh blood types were not linked with prognosis for overall survival.
引用
收藏
页码:S747 / S751
页数:5
相关论文
共 50 条
  • [1] Distributions and prognostic effects of ABO/Rh blood groups in patients with HER2/neu positive gastric and gastroesophageal junction cancer
    Dogan, Izzet
    Gurbuz, Mustafa
    Aydin, Esra
    Karabulut, Senem
    Tastekin, Didem
    Utkan, Gungor
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (SUPPL 2) : S747 - S751
  • [2] ABO and Rh blood groups frequency in women with HER2 positive breast cancer
    Urun, Y.
    Utkan, G.
    Altundag, K.
    Arslan, O.
    Onur, H.
    Arslan, U. Y.
    Kocer, M.
    Dogan, I.
    Senler, F. C.
    Yalcin, B.
    Demirkazik, A.
    Akbulut, H.
    Icli, F.
    JOURNAL OF BUON, 2012, 17 (03): : 457 - 460
  • [3] Prognostic significance of HER2/neu expression in gastric cancer
    Ananiev, Julian
    Gulubova, Maya
    Manolova, Irena
    Tchernev, Georgi
    WIENER KLINISCHE WOCHENSCHRIFT, 2011, 123 (13-14) : 450 - 454
  • [4] HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
    Eric Van Cutsem
    Yung-Jue Bang
    Feng Feng-yi
    Jian M. Xu
    Keun-Wook Lee
    Shun-Chang Jiao
    Jorge León Chong
    Roberto I. López-Sanchez
    Timothy Price
    Oleg Gladkov
    Oliver Stoss
    Julie Hill
    Vivian Ng
    Michaela Lehle
    Marlene Thomas
    Astrid Kiermaier
    Josef Rüschoff
    Gastric Cancer, 2015, 18 : 476 - 484
  • [5] HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
    Van Cutsem, Eric
    Bang, Yung-Jue
    Feng-Yi, Feng
    Xu, Jian M.
    Lee, Keun-Wook
    Jiao, Shun-Chang
    Chong, Jorge Leon
    Lopez-Sanchez, Roberto I.
    Price, Timothy
    Gladkov, Oleg
    Stoss, Oliver
    Hill, Julie
    Ng, Vivian
    Lehle, Michaela
    Thomas, Marlene
    Kiermaier, Astrid
    Rueschoff, Josef
    GASTRIC CANCER, 2015, 18 (03) : 476 - 484
  • [6] Prognostic value of immunohistochemical marker HER2/neu in patients resected for gastric cancer stage IIIA
    Levik, E. N.
    ZAPOROZHYE MEDICAL JOURNAL, 2014, (02) : 44 - 47
  • [7] Evaluation of Prognostic Factors and Trastuzumab-based Treatments in HER2/Neu-positive Metastatic Gastric Cancer
    Dogan, Izzet
    Karabulut, Senem
    Tastekin, Didem
    Ferhatoglu, Ferhat
    Paksoy, Nail
    Sakar, Burak
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2022, 32 (08): : 1014 - 1019
  • [8] Prognostic and predictive factors for the efficacy and safety of trastuzumab deruxtecan in HER2-positive gastric or gastroesophageal junction cancer
    Jubashi, Amane
    Nakayama, Izuma
    Koganemaru, Shigehiro
    Sakamoto, Naoya
    Oda, Shioto
    Matsubara, Yuki
    Miyashita, Yu
    Sato, Seiya
    Ushiyama, Shinpei
    Kobayashi, Akinori
    Okazaki, Ukyo
    Okemoto, Dai
    Yamamoto, Kazumasa
    Mishima, Saori
    Kotani, Daisuke
    Kawazoe, Akihito
    Hashimoto, Tadayoshi
    Nakamura, Yoshiaki
    Kuboki, Yasutoshi
    Bando, Hideaki
    Kojima, Takashi
    Yoshino, Takayuki
    Miyaaki, Hisamitsu
    Nakao, Kazuhiko
    Shitara, Kohei
    GASTRIC CANCER, 2025, 28 (01) : 63 - 73
  • [9] A survival guide to HER2 testing in gastric/gastroesophageal junction carcinoma
    Subasinghe, Duminda
    Acott, Nathan
    Kumarasinghe, Marian Priyanthi
    Path, Dip
    GASTROINTESTINAL ENDOSCOPY, 2019, 90 (01) : 44 - 54
  • [10] HER2 Status in Gastric and Gastroesophageal Junction Cancer: Results of the Large, Multinational HER-EAGLE Study
    Kim, Woo-Ho
    Gomez-Izquierdo, Lourdes
    Vilardell, Felip
    Chu, Kent-Man
    Soucy, Genevieve
    dos Santos, Lucas V.
    Monges, Genevieve
    Viale, Giuseppe
    Brito, Maria Jose
    Osborne, Stuart
    Noe, Johannes
    Du, Xiang
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2018, 26 (04) : 239 - 245